Rethinking miRNAs in MSC-sEV therapeutics: implications for manufacture, mechanism of action, and development of robust potency CQAs

Abstract

Mesenchymal stromal cell-derived small extracellular vesicles (MSC-sEVs) have emerged as a promising cell-free alternative to MSC-based therapies, offering superior safety, scalability, and stability profiles. These nanosized vesicles are now widely regarded as the principal therapeutic effectors of MSCs, capable of recapitulating many of the benefits attributed to their parental cells. However, their successful clinical translation depends on overcoming key challenges, particularly those related to product variability, viral safety, and the definition of mechanistically relevant potency-associated critical quality attributes (CQAs). This review explores the sources of MSC-sEV variability, including MSC tissue origin, manufacturing parameters, and limitations associated with primary and pluripotent stem cell-derived MSCs. The use of immortalized monoclonal MSC lines is discussed as a potential solution to improve batch consistency. Regulatory frameworks such as the International Council for Harmonisation (ICH) guideline Q5A(R2) are also highlighted for ensuring viral safety in sEV manufacturing processes. A major focus is the critical evaluation of microRNAs (miRNAs) - long regarded as leading candidates for potency CQAs in MSC-sEV products. Despite their prevalence in the extracellular vesicle literature, mounting evidence challenges their functional relevance in therapeutic contexts. Studies consistently show that miRNAs are underrepresented in sEVs, occur at very low copy numbers, and lack essential components (e.g., Argonaute proteins) required for canonical RNA interference. Moreover, the efficiency of EV internalization and endosomal escape remains exceedingly low, rendering miRNA-based gene regulation mechanistically implausible at physiologically relevant doses. These findings call into question the widespread assumption that miRNAs are primary effectors of MSC-sEV activity.

Keywords

Mesenchymal stem/stromal cell (MSC) / small extracellular vesicle (sEV) / miRNA / critical quality attribute (CQA)

References

[1] Chopp M.Treatment of neural injury with marrow stromal cells.Lancet Neurol2002;1:92-100

[2] Haynesworth SE,Caplan AI.Cytokine expression by human marrow-derived mesenchymal progenitor cells in vitro: effects of dexamethasone and IL-1α.J Cell Physiol1996;166:585-92

[3] Caplan AI.Mesenchymal stem cells as trophic mediators.J Cell Biochem2006;98:1076-84

[4] Timmers L,Arslan F.Reduction of myocardial infarct size by human mesenchymal stem cell conditioned medium.Stem Cell Res2007;1:129-37

[5] Bruno S,Deregibus MC.Mesenchymal stem cell-derived microvesicles protect against acute tubular injury.J Am Soc Nephrol2009;20:1053-67 PMCID:PMC2676194

[6] Lai RC,Lee MM.Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury.Stem Cell Res2010;4:214-22

[7] Bruno S,Collino F.Renal regenerative potential of different extracellular vesicle populations derived from bone marrow mesenchymal stromal cells.Tissue Eng Part A2017;23:1262-73 PMCID:PMC5689130

[8] Witwer KW,Bruno S.Defining mesenchymal stromal cell (MSC)-derived small extracellular vesicles for therapeutic applications.J Extracell Vesicles2019;8:1609206 PMCID:PMC6493293

[9] Doeppner TR,Görgens A.Extracellular vesicles improve post-stroke neuroregeneration and prevent postischemic immunosuppression.Stem Cells Transl Med2015;4:1131-43 PMCID:PMC4572905

[10] Nawaz M,Vallabhaneni KC.Extracellular vesicles: evolving factors in stem cell biology.Stem Cells Int2016;2016:1073140 PMCID:PMC4663346

[11] Baek G,Kim Y,Choi C.Mesenchymal stem cell-derived extracellular vesicles as therapeutics and as a drug delivery platform.Stem Cells Transl Med2019;8:880-6 PMCID:PMC6708072

[12] Tertel T,Arsène P,Giebel B.EV products obtained from iPSC-derived MSCs show batch-to-batch variations in their ability to modulate allogeneic immune responses in vitro.Front Cell Dev Biol2023;11:1282860 PMCID:PMC10642442

[13] Hollmann J,Goetzke R.Genetic barcoding reveals clonal dominance in iPSC-derived mesenchymal stromal cells.Stem Cell Res Ther2020;11:105 PMCID:PMC7059393

[14] Friedenstein AJ,Lalykina KS.The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells.Cell Tissue Kinet1970;3:393-403

[15] Romanov YA,Merzlikina NV.Mesenchymal stem cells from human bone marrow and adipose tissue: isolation, characterization, and differentiation potentialities.Bull Exp Biol Med2005;140:138-43

[16] In ’t Anker PS,Kleijburg-van der Keur C.Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta.Stem Cells2004;22:1338-45

[17] Kestendjieva S,Tsvetkova G.Characterization of mesenchymal stem cells isolated from the human umbilical cord.Cell Biol Int2008;32:724-32

[18] Lian Q,Suan Yeo K.Derivation of clinically compliant MSCs from CD105+, CD24- differentiated human ESCs.Stem Cells2007;25:425-36

[19] Hynes K,Mrozik K,Bartold PM.Generation of functional mesenchymal stem cells from different induced pluripotent stem cell lines.Stem Cells Dev2014;23:1084-96 PMCID:PMC4015475

[20] Allan D,Lalu M.Mesenchymal stromal cell-derived extracellular vesicles for regenerative therapy and immune modulation: progress and challenges toward clinical application.Stem Cells Transl Med2020;9:39-46 PMCID:PMC6954691

[21] Madel RJ,Dittrich R.Independent human mesenchymal stromal cell-derived extracellular vesicle preparations differentially attenuate symptoms in an advanced murine graft-versus-host disease model.Cytotherapy2023;25:821-36

[22] Selich A,Hass R.Massive clonal selection and transiently contributing clones during expansion of mesenchymal stem cell cultures revealed by lentiviral RGB-barcode technology.Stem Cells Transl Med2016;5:591-601 PMCID:PMC4835246

[23] McLeod CM.On the origin and impact of mesenchymal stem cell heterogeneity: new insights and emerging tools for single cell analysis.Eur Cell Mater2017;34:217-31 PMCID:PMC7735381

[24] Chen TS,Yin Y.Enabling a robust scalable manufacturing process for therapeutic exosomes through oncogenic immortalization of human ESC-derived MSCs.J Transl Med2011;9:47 PMCID:PMC3100248

[25] Kraskiewicz H,Bielawska-Pohl A.Can supernatant from immortalized adipose tissue MSC replace cell therapy?.Stem Cell Res Ther2020;11:29 PMCID:PMC6975034

[26] Labusek N,Köster C.Extracellular vesicles from immortalized mesenchymal stromal cells protect against neonatal hypoxic-ischemic brain injury.Inflamm Regen2023;43:24 PMCID:PMC10108458

[27] Shekari F,Baharvand H.Cell culture-derived extracellular vesicles: considerations for reporting cell culturing parameters.J Extracell Biol2023;2:e115 PMCID:PMC11080896

[28] Patel DB,Santharam Y,Stroka KM.Impact of cell culture parameters on production and vascularization bioactivity of mesenchymal stem cell-derived extracellular vesicles.Bioeng Transl Med2017;2:170-9 PMCID:PMC5579732

[29] Almeria C,Weber V,Kasper C.Heterogeneity of mesenchymal stem cell-derived extracellular vesicles is highly impacted by the tissue/cell source and culture conditions.Cell Biosci2022;12:51 PMCID:PMC9063275

[30] Gimona M,Choo ABH.Critical considerations for the development of potency tests for therapeutic applications of mesenchymal stromal cell-derived small extracellular vesicles.Cytotherapy2021;23:373-80

[31] Bonsergent E,Buchrieser J,Théry C.Quantitative characterization of extracellular vesicle uptake and content delivery within mammalian cells.Nat Commun2021;12:1864 PMCID:PMC7994380

[32] O'Brien K,Mahjoum S,Breakefield XO.Uptake, functionality, and re-release of extracellular vesicle-encapsulated cargo.Cell Rep2022;39:110651 PMCID:PMC9074118

[33] Zickler AM,Gupta D.Novel endogenous engineering platform for robust loading and delivery of functional mRNA by extracellular vesicles.Adv Sci2024;11:e2407619 PMCID:PMC11558116

[34] Liang X,Xie J.Multimodal engineering of extracellular vesicles for efficient intracellular protein delivery.bioRxiv2023; bioRxiv:2023.04.30.535834

[35] Jahnke K.Membranes on the move: the functional role of the extracellular vesicle membrane for contact-dependent cellular signalling.J Extracell Vesicles2024;13:e12436 PMCID:PMC11035383

[36] Tan TT,Sim WK,Lim SK.Enhancing EV-cell communication through “External Modulation of Cell by EV” (EMCEV).Cytotherapy2025;27:1-6

[37] Tan TT.Relevance of RNA to the therapeutic efficacy of mesenchymal stromal/stem cells extracellular vesicles.RNA Biol2025;22:1-7 PMCID:PMC12064053

[38] Baglio SR,Koppers-Lalic D.Human bone marrow- and adipose-mesenchymal stem cells secrete exosomes enriched in distinctive miRNA and tRNA species.Stem Cell Res Ther2015;6:127 PMCID:PMC4529699

[39] De Luca L,Laurenzana I.MiRNAs and piRNAs from bone marrow mesenchymal stem cell extracellular vesicles induce cell survival and inhibit cell differentiation of cord blood hematopoietic stem cells: a new insight in transplantation.Oncotarget2016;7:6676-92 PMCID:PMC4872742

[40] Lai RC,Yeo RW.MSC secretes at least 3 EV types each with a unique permutation of membrane lipid, protein and RNA.J Extracell Vesicles2016;5:29828 PMCID:PMC4770866

[41] Kodali M,Reger RL.Intranasally administered human MSC-derived extracellular vesicles inhibit NLRP3-p38/MAPK signaling after TBI and prevent chronic brain dysfunction.Brain Behav Immun2023;108:118-34 PMCID:PMC9974012

[42] Kuchen S,Yamane A.Regulation of microRNA expression and abundance during lymphopoiesis.Immunity2010;32:828-39 PMCID:PMC2909788

[43] Hanson B,Zheng W.EV-mediated promotion of myogenic differentiation is dependent on dose, collection medium, and isolation method.Mol Ther Nucleic Acids2023;33:511-28 PMCID:PMC10432918

[44] Albanese M,Hüls C.MicroRNAs are minor constituents of extracellular vesicles that are rarely delivered to target cells.PLoS Genet2021;17:e1009951 PMCID:PMC8675925

[45] Chevillet JR,Ruf IK.Quantitative and stoichiometric analysis of the microRNA content of exosomes.Proc Natl Acad Sci U S A2014;111:14888-93 PMCID:PMC4205618

[46] Bissels U,Tomiuk S.Absolute quantification of microRNAs by using a universal reference.RNA2009;15:2375-84 PMCID:PMC2779673

[47] Chang J,Marks D.miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1.RNA Biol2004;1:106-13

[48] Denzler R,Stefano J,Stoffel M.Assessing the ceRNA hypothesis with quantitative measurements of miRNA and target abundance.Mol Cell2014;54:766-76 PMCID:PMC4267251

[49] Ho V,Willison KR,Donnelly LE.Single cell quantification of microRNA from small numbers of non-invasively sampled primary human cells.Commun Biol2023;6:458 PMCID:PMC10133449

[50] Liang Y,Wong L.Characterization of microRNA expression profiles in normal human tissues.BMC Genomics2007;8:166 PMCID:PMC1904203

[51] Valdmanis PN,Chu K.miR-122 removal in the liver activates imprinted microRNAs and enables more effective microRNA-mediated gene repression.Nat Commun2018;9:5321 PMCID:PMC6294001

[52] van Balkom BWM, Gremmels H, Giebel B, Lim SK. Proteomic signature of mesenchymal stromal cell-derived small extracellular vesicles.Proteomics2019;19:e1800163

[53] Chen TS,Lee MM,Lee CN.Mesenchymal stem cell secretes microparticles enriched in pre-microRNAs.Nucleic Acids Res2010;38:215-24 PMCID:PMC2800221